These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37658802)

  • 1. A Comparison of the Prognostic Value of Liver Fibrosis Scores in Acute Myocardial Infarction Patients With and Without Type 2 Diabetes.
    He HM; Zheng SW; Chen YN; Zhu LY; Wang Z; Jiao SQ; Yang FR; Sun YH
    Angiology; 2024 Mar; 75(3):219-230. PubMed ID: 37658802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Value of the Age-D-Dimer-Albumin Score in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    He HM; Chen YN; Zeng JL; Zheng SW; Zhu LY; Wang Z; Jiao SQ; Yang FR; Sun YH
    Thromb Haemost; 2024 Feb; 124(2):166-176. PubMed ID: 37643748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention.
    Liu HH; Cao YX; Jin JL; Hua Q; Li YF; Guo YL; Zhu CG; Wu NQ; Gao RL; Li JJ
    J Am Heart Assoc; 2021 Feb; 10(3):e018869. PubMed ID: 33506689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
    Younes R; Caviglia GP; Govaere O; Rosso C; Armandi A; Sanavia T; Pennisi G; Liguori A; Francione P; Gallego-Durán R; Ampuero J; Garcia Blanco MJ; Aller R; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; Pareja MJ; Zaki MYW; Grieco A; Fracanzani AL; Valenti L; Miele L; Fariselli P; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
    J Hepatol; 2021 Oct; 75(4):786-794. PubMed ID: 34090928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
    Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
    Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between thrombolysis in myocardial infarction risk index and the severity of coronary artery lesions and long-term outcome in acute myocardial infarction patients undergoing percutaneous coronary intervention].
    Chen Y; Song Y; Xu JJ; Tang XF; Wang HH; Jiang P; Jiang L; Liu R; Zhao XY; Gao LJ; Song L; Zhang Y; Chen J; Gao Z; Qiao SB; Yang YJ; Gao RL; Xu B; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Nov; 46(11):874-881. PubMed ID: 30462976
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparison of the predictive value of the modified CADILLAC, GRACE and TIMI risk scores for the risk of short-term death in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention].
    Ji C; Song F; Huang X; Qu X; Qiu N; Zhu J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Mar; 35(3):299-304. PubMed ID: 36916344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis.
    Yan Z; Liu Y; Li W; Zhao X; Lin W; Zhang J; Yu S; Ma J; Wang J; Yu P; Li W; Liu X
    Eur J Clin Invest; 2022 Nov; 52(11):e13855. PubMed ID: 36001034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive value of hemoglobin to serum creatinine ratio combined with serum uric acid for in-hospital mortality after emergency percutaneous coronary intervention in patients with acute myocardial infarction].
    Bao F; Yang C; Zhou G
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Sep; 35(9):951-957. PubMed ID: 37803954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients.
    Ito T; Nguyen VH; Tanaka T; Park H; Yeh ML; Kawanaka M; Arai T; Atsukawa M; Yoon EL; Tsai PC; Toyoda H; Huang JF; Henry L; Jun DW; Yu ML; Ishigami M; Nguyen MH; Cheung RC
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1013-1022.e6. PubMed ID: 35654298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
    Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of nutritional status on prognosis in acute myocardial infarction patients undergoing percutaneous coronary intervention.
    Kanda D; Ikeda Y; Takumi T; Tokushige A; Sonoda T; Arikawa R; Anzaki K; Kosedo I; Ohishi M
    BMC Cardiovasc Disord; 2022 Jan; 22(1):3. PubMed ID: 34996387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of non-invasive liver fibrosis scores for mortality and complications development in individuals with type 2 diabetes.
    Leite NC; Cardoso CRL; Salles GF
    J Diabetes Complications; 2021 May; 35(5):107879. PubMed ID: 33573891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
    Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
    World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study.
    Choi SW; Kweon SS; Lee YH; Ryu SY; Nam HS; Shin MH
    PLoS One; 2022; 17(12):e0277729. PubMed ID: 36512564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.